Navigation Links
Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Date:11/16/2011

AMSTERDAM, November 17, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today provided its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2011.

3Q 2011 Highlights

  • Glybera® Marketing Authorisation Application filed for re-examination
  • Exclusive license signed with National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications
  • Dr. Carlos R. Camozzi appointed as Chief Medical Officer

CHMP Decision on Glybera and Re-organization

  • Glybera Marketing Authorisation Application re-examination:
    • Committee for Advanced Therapies (CAT), Scientific Advisory Group (SAG) and new Rapporteur/Co-Rapporteur all recommended Glybera approvable under exceptional circumstances
    • CHMP concluded that there are no significant safety issues with Glybera
    • CHMP concluded that insufficient evidence of clinical benefit means Glybera is not approvable at this time
  • AMT will focus development efforts and financial resources on three gene therapy programs: hemophilia B, GDNF and acute intermittent porphyria
  • Company remains committed to participating in the Sanfilippo B program, which is fully funded by a consortium led by Institut Pasteur
  • Further investment in and development of Glybera and Duchenne's muscular dystrophy programs suspended
  • AMT management is working in close consultation with the AMT Works Council to assess the impact of the review on the Company's workforce
  • Management and board believe that for AMT to remain a viable business it needs to reduce the headcou
    '/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ... Oral Amphotericin B (Oral Amp B) drug candidate ... ImmuneCarta®, the immune monitoring business unit of Caprion, ... Amp B in reactivating latent HIV viral reservoirs ... with antiretroviral therapy. Memory cells, ...
(Date:8/18/2014)... Tampa, FL (Aug. 18, 2014) -- A new ... South Florida (USF) Morsani College of Medicine and ... the life-threatening complications of interventional cardiovascular disease treatment. ... model that the novel molecular therapy could selectively ... healing following a medical procedure using a balloon ...
(Date:8/18/2014)... 2014   Sterne, Kessler, Goldstein & Fox P.L.L.C. ... Washington, DC , announced today that it has ... (IPR) with the U.S. Patent and Trademark Office (USPTO) ... Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions aim to ... Genetics, Inc. These patents have been asserted against GeneDx ...
(Date:8/18/2014)... YORK , August 18, 2014 ... published by Transparency Market Research "Life Science Reagents ... Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and ... and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- ... Forecast, 2013 - 2019", the global life science ...
Breaking Biology Technology:iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... Quarterly presents a 360-degree look at the "state of ... drugs. This CQ Forum will include a panel discussion ... regarding the complex structures of biologics products vs. traditional ... these products save money for consumers? What is the ...
... June 15 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: ... new class of small molecule compounds based on endogenous adrenal ... James M. Frincke Ph.D. as President and CEO of Hollis-Eden ... company,s board of directors. , , Dr. Frincke joined ...
... June 15 Nanopoint Inc., an award-winning developer ... announced that effective immediately its cellTRAY Imaging System ... European marketplace. Nanopoint,s cellTRAY Imaging and Fluidics Systems ... including drug discovery, assisted reproductive technology (ART), stem ...
Cached Biology Technology:Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 2Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 3Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems 2
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
(Date:8/19/2014)... retail seafood counters in 10 different states show ... to unexpectedly high levels of mercury, a harmful ... fish of the same species, but from a ... according to new research by University of Hawai,i ... is essential to allow consumers to choose sustainable ...
(Date:8/19/2014)... identified a biomarker strongly associated with basal-like breast ... to many types of chemotherapy. The biomarker, a ... new therapeutics designed to treat this often deadly ... from The Cancer Genome Atlas, molecular biologists Curt ... computational and bioinformatics techniques to detect patterns of ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... and vegetables instead of cookies and soda pop. Consider ... applaud a lunchtime workout rather than criticizing the cut ... encourages walking the stairs instead of riding the elevator. ... by Community Health Councils, Inc. (CHC) in Los Angeles ...
... Cold Spring Harbor Laboratory on Long Island have identified which ... the chief target of the widely prescribed antidepressant Prozac. This ... for depression, with fewer side effects, to be developed. , ... the factors that control how, when, and where new neurons ...
... tumor and settles in a new location, where it ... assays for this process, which is known as metastasis, ... across the surface of a matrix, traveling in a ... approach misses some crucial phenomena. , Working in the ...
Cached Biology News:UCLA study of community health project shows how group dynamics affect fitness, eating habits 2UCLA study of community health project shows how group dynamics affect fitness, eating habits 3Prozac's target revealed 23-D model reveals secrets of metastasis 2
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
... processes up to 48 lanes, 24 bi-directional, ... can be from either slab gel or ... chemistries. The detection parameters in Explorer have ... consistency. We have built Explorer for ...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: